Your browser doesn't support javascript.
loading
Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment.
Santos, Raul D; Ruzza, Andrea; Wang, Bei; Maruff, Paul; Schembri, Adrian; Bhatia, Ajay K; Mach, François; Bergeron, Jean; Gaudet, Isabelle; St Pierre, Julie; Kastelein, John J P; Hovingh, G Kees; Wiegman, Albert; Gaudet, Daniel; Raal, Frederick J.
Afiliación
  • Santos RD; Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School Hospital and Hospital Israelita Albert Einstein, Av. Dr Enéas C. Aguiar 44, Sao Paulo 05403-900, Brazil.
  • Ruzza A; Global Development, Amgen, Thousand Oaks, CA, USA.
  • Wang B; Biostatistics Department, Amgen, Thousand Oaks, CA, USA.
  • Maruff P; Cogstate Ltd., Melbourne, VIC, Australia.
  • Schembri A; Cogstate Ltd., Melbourne, VIC, Australia.
  • Bhatia AK; Global Development, Amgen, Thousand Oaks, CA, USA.
  • Mach F; Cardiology Department, Geneva University Hospital, Geneva, Switzerland.
  • Bergeron J; Lipid Clinic, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Quebec, QC, Canada.
  • Gaudet I; Department of Health Sciences, Université du Quebec à Chicoutimi, and ECOGENE-21, Chicoutimi, QC, Canada.
  • St Pierre J; Department of Pediatrics, Faculty of Medicine, McGill University, Montréal, QC, Canada.
  • Kastelein JJP; Department of Vascular Medicine, Amsterdam UMC, Amsterdam, Netherlands.
  • Hovingh GK; Department of Vascular Medicine, Amsterdam UMC, Amsterdam, Netherlands.
  • Wiegman A; Department of Pediatrics, Amsterdam UMC, Amsterdam, Netherlands.
  • Gaudet D; The Clinical Lipidology and Rare Lipid Disorders Unit, Community Genomic Medicine Centre and ECOGENE-21, Department of Medicine, Université de Montréal, Chicoutimi, QC, Canada.
  • Raal FJ; Division of Endocrinology and Metabolism, Department of Medicine Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Eur J Prev Cardiol ; 31(3): 302-310, 2024 Feb 15.
Article en En | MEDLINE | ID: mdl-37855448
Some children are born with a genetic disorder that causes high cholesterol, which leads to heart disease. Children with high cholesterol can be treated with evolocumab, a medication that lowers blood cholesterol. Because cholesterol is important for development and adequate function of the brain, there is a concern that lowering cholesterol in children may affect mental ability. In this study, we tested whether treating children with evolocumab for 80 weeks affected mental ability in performing several tasks. A battery of tests that measure executive function (Groton Maze Learning Test), visual learning (One Card Learning Test), visual attention (Identification Test), and psychomotor function (Detection Test) showed no decrease in performance across visits during 80 weeks of evolocumab treatment. Performance on all tasks was similar for the children who received placebo for the first 24 weeks then received evolocumab for an additional 80 weeks (placebo/evolocumab) and those who received evolocumab for 24 weeks then received evolocumab for an additional 80 weeks (evolocumab/evolocumab).
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Hiperlipoproteinemia Tipo II / Anticolesterolemiantes Límite: Adult / Child / Humans Idioma: En Revista: Eur J Prev Cardiol Año: 2024 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Hiperlipoproteinemia Tipo II / Anticolesterolemiantes Límite: Adult / Child / Humans Idioma: En Revista: Eur J Prev Cardiol Año: 2024 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Reino Unido